This viewpoint highlights the US FDA's decision to eliminate risk management for CAR T-cell therapies, suggesting increased access for cancer patients.
This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.
No takes yet. Share an insight, caveat, or question.
Das et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: